TP53 and B-cell chronic lymphocytic leukemia: Nevertheless, it has to be remarked that BRB affected viability and proliferation also of CLL cells from patients with markers of aggressive disease, such as those harboring 17p deletion, TP53 and SF3B1 mutations, or other chromosomal abnormalities known to confer chemoresistance.